This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CollabRx Partners With Sengenics For Molecular Diagnostics

SAN FRANCISCO, April 9, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), today announced a partnership with Sengenics, a leading genetic diagnostics company, to provide turn-key diagnostic decision making solutions for Asian and global markets. Sengenics plans to incorporate CollabRx's interpretive content resources into its molecular cancer diagnostics tests and reports.

"Sengenics has become a widely recognized pioneer in this field, as it was the first company outside the US to offer genomics-based research and diagnostic services," said CollabRx Chairman, President and Chief Executive Officer Thomas Mika. "We look forward to partnering with Sengenics on a powerful joint offering in clinical cancer sequencing."

Sengenics plans to offer cancer exome sequencing tests combined with CollabRx interpretive analytics to create a comprehensive medical informatics solution. The solution is being designed to seamlessly pair tests results with clinically actionable and dynamically updated knowledge on the clinical impact of specific tumor genetic profiles and associated therapeutic strategies such as drugs and clinical trials. CollabRx will provide the content in a SaaS-based business model.

"We are excited about partnering with CollabRx and developing such an important turn-key solution for clinical cancer sequencing," said Dr. Anwar, Executive Director of Sengenics. "Our joint solution's ability to provide insights from CollabRx's clinical practitioner network represents critical and timely value to physicians when they are interpreting test results."

The partnership leverages CollabRx's semantic integration platform, a scalable, proprietary technology that enables CollabRx scientists and physicians to dynamically update the company's molecular oncology knowledge base with the latest medical and scientific data available in the public domain.

The partnership, leveraging on Sengenics' status as a prominent commercial entity in the genomics and diagnostics space, extends CollabRx's business to three continents: North America, Europe and Asia.

"CollabRx has established an industry standard for interpretive reporting in cancer diagnostics which this agreement helps to expand globally," said Mr. Mika. "We also look forward to working with Sengenics to expand our interpretive content to genomic disease areas outside of cancer."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.75 -1.10%
FB $117.53 0.69%
GOOG $693.00 0.29%
TSLA $240.75 -2.80%
YHOO $36.61 0.06%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.87 -9.94 -0.48%
NASDAQ 4,775.8150 -29.4760 -0.61%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs